Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 4, 2018

Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo

GlobeNewswire December 19, 2017

Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)

GlobeNewswire December 15, 2017

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences

PR Newswire December 7, 2017

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Benzinga.com  November 30, 2017

Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor

GlobeNewswire November 21, 2017

Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

GlobeNewswire November 9, 2017

Aclaris Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 7, 2017

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire November 3, 2017

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 2, 2017

Aclaris Therapeutics to Announce Third Quarter 2017 Financial Results on November 7, 2017

GlobeNewswire October 31, 2017

Aclaris Therapeutics Announces the Allowance of a U.S. Patent Application and Issuance of a Japanese Patent Covering Tofacitinib for Treating Hair Loss Disorders

GlobeNewswire October 24, 2017

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire October 6, 2017

Best Places to Work in PA 2017

GlobeNewswire October 2, 2017

Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York

GlobeNewswire September 20, 2017

Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis

GlobeNewswire September 19, 2017

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 7, 2017

Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders

GlobeNewswire September 5, 2017

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire August 17, 2017

Aclaris Announces Proposed Public Offering of Common Stock

GlobeNewswire August 9, 2017